Understand the source comparison
Comparison: Research-Grade Anxiolytic Peptides
Selank GABA-A receptor modulation, enkephalin metabolism inhibition Intranasal spray Strong (multiple RCTs in GAD, social anxiety) 30–60 minutes Most robust clinical data for anxiety-specific use; non-sedating; no tolerance development Cerebrolysin BDNF and NG
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Selank
- GABA-A receptor modulation, enkephalin metabolism inhibition
- Intranasal spray
- Strong (multiple RCTs in GAD, social anxiety)
- 30–60 minutes
- Most robust clinical data for anxiety-specific use; non-sedating; no tolerance development
- Cerebrolysin
- BDNF and NGF pathway activation
- IV or subcutaneous injection
- Moderate (secondary anxiety outcomes in neurological trials)
- 7–14 days (cumulative)
- Effective for anxiety secondary to neurological conditions; requires clinical administration
- P21
- Hippocampal neurogenesis, BDNF upregulation
- Subcutaneous injection
- Weak (one pilot study in healthy volunteers)
- 14–21 days (cumulative)
- Investigational; promising preclinical data but limited human anxiety trials
- Thymalin
- HPA axis regulation, cortisol normalization
- Subcutaneous or intramuscular injection
- Weak (immune-focused trials with anxiety as secondary measure)
- 10–14 days
- Indirect anxiolytic effect through stress hormone regulation; not anxiety-specific